The Role of Estrogen Receptor–Targeted PET with 16α- 18 F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis
Journal of Nuclear Medicine · 2026-01 · 67 (1) · 36-42
DOI: 10.2967/jnumed.125.270763 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.12.2025. Verfasst von Jennifer M Specht und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Fred Hutchinson Cancer Center Clinical Research Division, Department of Medicine, University of Washington, Seattle, Wa…. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Estradiol, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
[18F]16α-fluoro-17β-fluoroestradiol ([18F]FES) PET/CT imaging enables whole-body assessment of functional estrogen receptor (ER) expression in metastatic breast cancer (mBC). Identifying imaging biomarkers that predict endocrine therapy (ET) response remains a critical need in optimizing treatment selection. Our objective was to assess the predictive utility of [18F]FES PET/CT imaging in determining response to ET, with a focus on interlesional heterogeneity and individual patient outcomes.
Methods
A systematic literature review and metaanalysis were conducted using 6 major databases through April 2024. Ten studies met inclusion criteria based on quantitative SUV reporting, use of FES PET/CT in mBC, and correlation with clinical outcomes. All patients had ER-positive mBC and received ET. Primary endpoints included progression-free survival (PFS) and response to ET. Patients were stratified by baseline [18F]FES PET/CT SUVmean or SUVmax thresholds (including 1.8) and by interlesional [18F]FES heterogeneity (presence of both [18F]FES-positive and [18F]FES-negative lesions).
Results
Responders had a significantly higher baseline SUVmean than nonresponders (standardized mean difference, 0.91; 95% CI, 0.49-1.34; P < 0.001). Patients with a baseline SUVmax below 1.5 were significantly less likely to respond (odds ratio, 0.11; 95% CI, 0.02-0.72; P = 0.02). Across 5 studies, patients with heterogeneous [18F]FES uptake had a shorter median PFS (2.4-12.4 mo) than did those with all [18F]FES-positive lesions (14.6-23.6 mo), a statistically significant difference (ratio of median PFS, 0.25; 95% CI, 0.17-0.36; P < 0.001). In an individual-level analysis (n = 101), lesion-level [18F]FES-heterogeneous uptake was associated with a PFS of 5.5 versus 21.6 mo and a hazard ratio of 5.4 (95% CI, 3.2-9.4; P < 0.001). An [18F]FES SUVmax threshold of at least 1.8 was more prognostic of PFS than were higher SUVmax thresholds. Conclusion: [18F]FES PET/CT imaging provides prognostic insight beyond static ER testing by identifying functional heterogeneity in mBC. Lesion-level FES heterogeneity based on an SUVmax threshold of 1.8 may help stratify patients unlikely to benefit from ET, guiding more personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Fred Hutchinson Cancer Center Clinical Research Division, Department of Medicine, University of Washington, Seattle, Washington.
- Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and.
- Medical Affairs, GE HealthCare, Chicago, Illinois.
- Division of Medical Oncology, Fred Hutchinson Cancer Center Clinical Research Division, Department of Medicine, University of Washington, Seattle, Washington; hmlinden@uw.edu.
Zitieren
APA
Specht, J. M., van Geel, J. J. L., Song, S., Liu, C., Hippe, D. S., DiGregorio, N. A., Brand, C. J., & Linden, H. M. (2026). The Role of Estrogen Receptor–Targeted PET with 16α- 18 F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis. Journal of Nuclear Medicine, 67(1), 36-42. https://doi.org/10.2967/jnumed.125.270763
Vancouver
Specht JM, van Geel JJL, Song S, Liu C, Hippe DS, DiGregorio NA, et al. The Role of Estrogen Receptor–Targeted PET with 16α- 18 F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis. Journal of Nuclear Medicine. 2026;67(1):36-42. doi:10.2967/jnumed.125.270763
BibTeX
@article{Specht2026,
author = {Specht, Jennifer M and van Geel, Jasper J L and Song, Shaoli and Liu, Cheng and Hippe, Daniel S and DiGregorio, Nicholas A and Brand, Christine J and Linden, Hannah M},
title = {The Role of Estrogen Receptor–Targeted PET with 16α- 18 F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {1},
pages = {36--42},
doi = {10.2967/jnumed.125.270763}
}
EUVIMED